Pharmaceutical

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

Ligand Pharmaceuticals has announced a definitive agreement for the acquisition of APEIRON Biologics in a deal worth $100m in cash.

Jul 10, 2024 - 04:00
Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m
Ligand Pharmaceuticals has announced a definitive agreement for the acquisition of APEIRON Biologics in a deal worth $100m in cash.
Read the original article

Tags:

Previous Article

Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia

Next Article

Moderna and Mitsubishi Tanabe link on mRNA vaccines in Japan

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Former Sage executives join biotech VC Cure Ventures

STAT+: Former Sage executives join biotech VC Cure Vent...

Jan 8, 2024

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval

Sanofi/Regeneron’s Dupixent set to dominate COPD biolog...

Sep 28, 2024

STAT+: Results on Novartis prostate cancer therapy could expand its use

STAT+: Results on Novartis prostate cancer therapy coul...

Oct 24, 2023